Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy

Journal of Clinical Oncology

Volumn 26, Issue 26, 2008, Pages 4326-4332

  Bunin, Nancy J ^a   Davies, Stella M ^a   Aplenc, Richard ^a   Camitta, Bruce M ^a   DeSante, Kenneth B ^a   Goyal, Rakesh K ^a   Kapoor, Neena ^a   Kernan, Nancy A ^a   Rosenthal, Joseph ^a   Smith, Franklin O ^a   Eapen, Mary ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; DISEASE FREE SURVIVAL; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REMISSION; RISK FACTOR; SURVIVAL RATE; T CELL DEPLETION; TREATMENT FAILURE; MORTALITY; PRESCHOOL CHILD;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK FACTORS; TISSUE DONORS;

EID: 52049117651     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.4442     Document Type: Article

References (22)

1. Creutzig U, Zimmermann M, Ritter J, et al: Treatment strategies and long-term results In paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030-2042, 2005
2. Gibson BE, Wheatley K, Hann IM, et al: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19:2130-2138, 2005
3. Ravindranath Y, Chang M, Steuber CP, et al: Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-2116, 2005
4. Ribeiro RC, Razzouk Bl, Pounds S, et al: Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia 19:2125-2129, 2005
5. Smith FO, Alonzo TA, Gerbing RB, et al: Long-term results of children with acute myeloid leukemia: A report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 19:2054-2062, 2005
6. Woods WG, Neudorf S, Gold S, et al: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 97:56-62, 2001
7. Aladjidi N, Auvrignon A, Leblanc T, et al: Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 21:4377-4385, 2003
8. Johnston DL, Alonzo TA, Gerbing RB, et al: Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 23:9172-9178, 2005
9. Rubnitz JE, Razzouk Bl, Lensing S, et al: Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 109:157-163, 2007
10. Stahnke K, Boos J, Bender-Gotze C, et al: Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12:1534-1538, 1998
11. Webb DK, Wheatley K, Harrison G, et al: Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial: MRC Childhood Leukaemia Working Party. Leukemia 13:25-31, 1999
12. Wells RJ, Adams MT, Alonzo TA, et al: Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 21:2940-2947, 2003
13. Farag SS, Bacigalupo A, Eapen M, et al: The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 12:876-884, 2006
14. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
15. Flowers ME, Kansu E, Sullivan KM: Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 13:1091-1112, 1999
16. Klein JP, Moeschberger ML: Survival Analysis: Techniques of Censored and Truncated Data (ed 2). New York, NY, Springer-Verlag, 2003
17. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-200, 1972
18. Andersen PK, Klein JP, Zhang MJ: Testing for centre effects in multi-centre survival studies: A Monte Carlo comparison of fixed and random effects tests. Stat Med 18:1489-1500, 1999
19. Eapen M, Rubinstein P, Zhang MJ, et al: Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. Lancet 369:1947-1954, 2007
20. Locatelli F, Labopin M, Ortega J, et al: Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 101: 1611-1619, 2003
21. Wagner JE, Thompson JS, Carter SL, et al: Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): A multi-centre, randomised phase ll-lll trial. Lancet 366:733-741, 2005
22. Lee SJ, Klein J, Haagenson M, et al: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:4576-4583, 2007